Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$185.72MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christopher Peetz
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 433
- Beta
- 0.49
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -0.50
Financials
Revenue
$185.72M+1588.4%Net Income
$-40.77MEBITDA
$-31.73M-838.1%Free Cash Flow
$-5.62MEPS (diluted)
$-0.62Shares Outstanding (diluted)
66.05M+560.1%Operating Expenses
$196.79MCash & Debt
$373.69MRevenue by Segment (annual)
$521.31MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $521.31M | $-23.36M | $-0.47 |
| 2024 | $336.89M | $-87.94M | $-1.85 |
| 2023 | $186.37M | $-163.41M | $-4.00 |
| 2022 | $77.06M | $-135.66M | $-4.01 |
| 2021 | $19.14M | $-83.99M | $-2.77 |
| 2020 | $0.00 | $-103.27M | $-4.09 |
| 2019 | $0.00 | $-52.55M | $-2.29 |
| 2018 | $0.00 | $-17.35M | $-0.75 |
Valuation
MIRMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
10-80.00%Social Signal Score
Mentions (30)
- Newsreuters.com·12d ago·Negative
Mirum's liver infection drug lowers virus levels in second late-stage study Mirum's liver infection drug lowers virus levels in second late-stage study
View source ↗ - News (RSS)seekingalpha·18d ago·Neutral
Mirum outlines $715M to $720M 2026 net product sales guidance while targeting cash flow positive next year
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 Earnings Call Transcript Mirum Pharmaceuticals, Inc. ( MIRM ) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher Peetz - CEO & Director Peter Radovich - COO & President Rob Myers - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Luke Herrm…
View source ↗ - Newsmarketbeat.com·19d ago·Neutral
Mirum Pharmaceuticals Q3 Earnings Call Highlights Mirum Pharmaceuticals NASDAQ: MIRM reported third-quarter net product sales of $186 million and raised its full-year 2026 net product sales guidance to $715 million to $720 million, citing continued growth of LIVMARLI and its bile acid medicines as well as progress across its late-stage pipeline.
View source ↗ - Newszacks.com·19d ago·Neutral
Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings While the top- and bottom-line numbers for Mirum Pharmaceuticals (MIRM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newszacks.com·19d ago·Negative
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to earnings of $0.05 per share a year ago.
View source ↗ - Newszacks.com·26d ago·Neutral
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newszacks.com·40d ago·Negative
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases MIRM's Livmarli meets the phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids, with an FDA filing planned for 2027.
View source ↗ - News (Marketaux)gurufocus.com·41d ago·Positive
Mirum Pharmaceuticals, Inc. Business Update Call Transcript Oct 12, 2026 / 12:30PM GMT Operator [+306 characters]
View source ↗ - News (RSS)seekingalpha·41d ago·Positive
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript
View source ↗ - News (RSS)seekingalpha·41d ago·Neutral
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia - Slideshow
View source ↗ - Newsseekingalpha.com·41d ago·Positive
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript
View source ↗ - Newsmarketbeat.com·41d ago·Neutral
Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases Mirum Pharmaceuticals NASDAQ: MIRM said its Phase III EXPAND study of LIVMARLI, or maralixibat, met its primary endpoint and all prespecified secondary endpoints in pediatric patients with cholestatic pruritus associated with ultra-rare cholestatic liver diseases.
View source ↗ - News (RSS)seekingalpha·42d ago·Neutral
Mirum Pharmaceuticals to report Livmarli trial results Monday
View source ↗ - News (RSS)investing·42d ago·Neutral
Mirum Pharmaceuticals to share phase 3 LIVMARLI study results
View source ↗ - Newsbusinesswire.com·42d ago·Neutral
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum to Host Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases.
View source ↗ - Newsmarketbeat.com·51d ago·Neutral
Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study Mirum Pharmaceuticals NASDAQ: MIRM reported positive top-line results from the Phase III portion of its AZURE-1 study evaluating brelovitug for chronic hepatitis delta, saying the investigational antibody met its primary endpoint at 24 weeks and showed a favorable tolerability profile.
View source ↗ - News (Marketaux)gurufocus.com·54d ago·Positive
MIRM Maintained by Baird -- Price Target Raised to $130 Mirum Pharmaceuticals [+229 characters]
View source ↗ - News (RSS)seekingalpha·55d ago·Positive
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript
View source ↗ - News (RSS)seekingalpha·55d ago·Neutral
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta - Slideshow
View source ↗ - Newszacks.com·55d ago·Negative
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduction in new HO lesion volume.
View source ↗ - News (RSS)investing·56d ago·Neutral
Mirum to present phase 3 hepatitis delta study results Monday
View source ↗ - Newsbusinesswire.com·56d ago·Neutral
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic HDV on September 28, 2026.
View source ↗ - News (RSS)seekingalpha·57d ago·Neutral
Mirum and Incyte gain approval of zilurgisertib for rare bone disorder
View source ↗ - Newsreuters.com·58d ago·Negative
US FDA approves Mirum's drug for rare bone disorder The US Food and Drug Administration has approved Mirum Pharmaceuticals' drug to treat a rare bone disorder, the regulator said on Friday.
View source ↗ - Newsseekingalpha.com·67d ago·Positive
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Mirum Pharmaceuticals, Inc. (MIRM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·67d ago·Neutral
…ching major catalysts, notably the FDA's PDUFA decision for zilurgisertib (Sept. 26) & pivotal Phase 3 data on its chronic hepatitis D drug, a potential blockbuster. MIRM's pipeline expansion and strategic acquisitions have delayed profitability to 2028, but management raised FY 2026 sales guidance to $680–$700 million. Strong commercial traction from LIVMARLI and bile acid products drove Q2 revenue above expectations, but operating losses widened due to R&D and integration costs.
View source ↗ - News (RSS)seekingalpha·68d ago·Neutral
Mirum Pharmaceuticals: The September PDUFA Is The Smallest Catalyst
View source ↗ - Newszacks.com·79d ago·Neutral
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report? Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
View source ↗
Earnings
Wed, Feb 24(in 3 months)
Consensus estimate $-0.67 per share
Typical surprise -42.8% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$-0.87 vs $-0.49miss
- Wed, Aug 5$-1.06 vs $-0.74miss
- Wed, May 6$-13.43 vs $-0.40miss
- Wed, Feb 25$-0.11 vs $0.02miss
- Tue, Nov 4$0.05 vs $-0.10beat
- Wed, Aug 6$-0.12 vs $-0.31beat
Estimates and results for MIRM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MIRM officers and directors.
- Bought
- —
- Sold
- $23.2m
0 trades
38 trades
- Ramasastry Sairasold
- Brege Laurasold
- Brege Laurasold
- Peetz Christophersold
- Bjerkholt Ericsold
- Howe Jolandasold
- Peetz Christophersold
- Peetz Christophersold
62 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MIRM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
